Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Non-Current Deffered Revenue (2016 - 2025)

Apyx Medical (APYX) has disclosed Non-Current Deffered Revenue for 11 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 6.08% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Dec 2025, down 6.08%, and an annual FY2025 reading of $1.0 million, down 6.08% over the prior year.
  • Non-Current Deffered Revenue was $1.0 million for Q4 2025 at Apyx Medical, down from $1.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $1.4 million in Q4 2022 and bottomed at $855000.0 in Q1 2021.
  • Average Non-Current Deffered Revenue over 5 years is $1.2 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 113.04% in 2021, then dropped 11.51% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $1.3 million in 2021, then increased by 6.42% to $1.4 million in 2022, then dropped by 11.51% to $1.2 million in 2023, then decreased by 10.27% to $1.1 million in 2024, then dropped by 6.08% to $1.0 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for APYX at $1.0 million in Q4 2025, $1.2 million in Q3 2025, and $1.2 million in Q2 2025.